541 related articles for article (PubMed ID: 23234763)
1. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Goss PE; Smith IE; O'Shaughnessy J; Ejlertsen B; Kaufmann M; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Chavarri-Guerra Y; Aktan G; Rappold E; Williams LS; Finkelstein DM;
Lancet Oncol; 2013 Jan; 14(1):88-96. PubMed ID: 23234763
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
3. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
5. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
6. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Emens LA; Esteva FJ; Beresford M; Saura C; De Laurentiis M; Kim SB; Im SA; Wang Y; Salgado R; Mani A; Shah J; Lambertini C; Liu H; de Haas SL; Patre M; Loi S
Lancet Oncol; 2020 Oct; 21(10):1283-1295. PubMed ID: 33002436
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Baselga J; Bradbury I; Eidtmann H; Di Cosimo S; de Azambuja E; Aura C; Gómez H; Dinh P; Fauria K; Van Dooren V; Aktan G; Goldhirsch A; Chang TW; Horváth Z; Coccia-Portugal M; Domont J; Tseng LM; Kunz G; Sohn JH; Semiglazov V; Lerzo G; Palacova M; Probachai V; Pusztai L; Untch M; Gelber RD; Piccart-Gebhart M;
Lancet; 2012 Feb; 379(9816):633-40. PubMed ID: 22257673
[TBL] [Abstract][Full Text] [Related]
14. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
16. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
17. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
20. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
